Monica G Valero1, Emily C Zabor2, Anna Park1, Elizabeth Gilbert1, Ashely Newman1, Tari A King3,4, Melissa L Pilewskie5. 1. Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. 2. Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA. 4. Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA. 5. Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. pilewskm@mskcc.org.
Abstract
BACKGROUND: The Tyrer-Cuzick model has been shown to overestimate risk in women with atypical hyperplasia, although its accuracy among women with lobular carcinoma in situ (LCIS) is unknown. We evaluated the accuracy of the Tyrer-Cuzick model for predicting invasive breast cancer (IBC) development among women with LCIS. METHODS: Women with LCIS participating in surveillance from 1987 to 2017 were identified from a prospectively maintained database. Tyrer-Cuzick score (version 7) was calculated near the time of LCIS diagnosis. Patients with prior or concurrent breast cancer, a BRCA mutation, receiving chemoprevention, or with pleomorphic LCIS were excluded. Invasive cancer-free probability was estimated using the Kaplan-Meier method. RESULTS: A total of 1192 women with a median follow-up of 6 years (interquartile range [IQR] 2.5-9.9) were included. Median age at LCIS diagnosis was 49 years (IQR 45-55), 88% were white; 37% were postmenopausal, 28% had ≥ 1 first-degree family member with breast cancer, and 13% had ≥ 2 second-degree family members with breast cancer. In total, 128 patients developed an IBC; median age at diagnosis was 54 years (IQR 49-61). Five- and 10-year cumulative incidences of invasive cancer were 8% (95% confidence interval [CI] 6-9%) and 14% (95% CI 12-17%), respectively. The median Tyrer-Cuzick 10-year risk score was 20.1 (IQR 17.4-24.3). Discrimination measured by the C-index was 0.493, confirming that the Tyrer-Cuzick model is not well calibrated in this patient population. CONCLUSIONS: The Tyrer-Cuzick model is not accurate and may overpredict IBC risk for women with LCIS, and therefore should not be used for breast cancer risk assessment in this high-risk population.
BACKGROUND: The Tyrer-Cuzick model has been shown to overestimate risk in women with atypical hyperplasia, although its accuracy among women with lobular carcinoma in situ (LCIS) is unknown. We evaluated the accuracy of the Tyrer-Cuzick model for predicting invasive breast cancer (IBC) development among women with LCIS. METHODS:Women with LCIS participating in surveillance from 1987 to 2017 were identified from a prospectively maintained database. Tyrer-Cuzick score (version 7) was calculated near the time of LCIS diagnosis. Patients with prior or concurrent breast cancer, a BRCA mutation, receiving chemoprevention, or with pleomorphic LCIS were excluded. Invasive cancer-free probability was estimated using the Kaplan-Meier method. RESULTS: A total of 1192 women with a median follow-up of 6 years (interquartile range [IQR] 2.5-9.9) were included. Median age at LCIS diagnosis was 49 years (IQR 45-55), 88% were white; 37% were postmenopausal, 28% had ≥ 1 first-degree family member with breast cancer, and 13% had ≥ 2 second-degree family members with breast cancer. In total, 128 patients developed an IBC; median age at diagnosis was 54 years (IQR 49-61). Five- and 10-year cumulative incidences of invasive cancer were 8% (95% confidence interval [CI] 6-9%) and 14% (95% CI 12-17%), respectively. The median Tyrer-Cuzick 10-year risk score was 20.1 (IQR 17.4-24.3). Discrimination measured by the C-index was 0.493, confirming that the Tyrer-Cuzick model is not well calibrated in this patient population. CONCLUSIONS: The Tyrer-Cuzick model is not accurate and may overpredict IBC risk for women with LCIS, and therefore should not be used for breast cancer risk assessment in this high-risk population.
Authors: Laura C Collins; Heather J Baer; Rulla M Tamimi; James L Connolly; Graham A Colditz; Stuart J Schnitt Journal: Cancer Date: 2006-09-15 Impact factor: 6.860
Authors: Judy C Boughey; Lynn C Hartmann; Stephanie S Anderson; Amy C Degnim; Robert A Vierkant; Carol A Reynolds; Marlene H Frost; V Shane Pankratz Journal: J Clin Oncol Date: 2010-07-06 Impact factor: 44.544
Authors: Amy C Degnim; Daniel W Visscher; Hal K Berman; Marlene H Frost; Thomas A Sellers; Robert A Vierkant; Shaun D Maloney; V Shane Pankratz; Piet C de Groen; Wilma L Lingle; Karthik Ghosh; Lois Penheiter; Thea Tlsty; L Joseph Melton; Carol A Reynolds; Lynn C Hartmann Journal: J Clin Oncol Date: 2007-06-11 Impact factor: 44.544
Authors: Tari A King; Shirin Muhsen; Sujata Patil; Starr Koslow; Sabine Oskar; Anna Park; Mary Morrogh; Rita A Sakr; Monica Morrow Journal: Breast Cancer Res Treat Date: 2013-10-19 Impact factor: 4.872
Authors: Jane Warwick; Hanna Birke; Jennifer Stone; Ruth M L Warren; Elizabeth Pinney; Adam R Brentnall; Stephen W Duffy; Anthony Howell; Jack Cuzick Journal: Breast Cancer Res Date: 2014-10-08 Impact factor: 6.466
Authors: Louisa Lisa Lo; Roger Laughlin Milne; Yuyan Liao; Jack Cuzick; Mary Beth Terry; Kelly-Anne Phillips Journal: Br J Cancer Date: 2018-06-21 Impact factor: 7.640
Authors: Adam R Brentnall; Elaine F Harkness; Susan M Astley; Louise S Donnelly; Paula Stavrinos; Sarah Sampson; Lynne Fox; Jamie C Sergeant; Michelle N Harvie; Mary Wilson; Ursula Beetles; Soujanya Gadde; Yit Lim; Anil Jain; Sara Bundred; Nicola Barr; Valerie Reece; Anthony Howell; Jack Cuzick; D Gareth R Evans Journal: Breast Cancer Res Date: 2015-12-01 Impact factor: 6.466
Authors: Constance D Lehman; Sarah Mercaldo; Leslie R Lamb; Tari A King; Leif W Ellisen; Michelle Specht; Rulla M Tamimi Journal: J Natl Cancer Inst Date: 2022-10-06 Impact factor: 11.816
Authors: Cong Liu; Nur Zeinomar; Wendy K Chung; Krzysztof Kiryluk; Ali G Gharavi; George Hripcsak; Katherine D Crew; Ning Shang; Atlas Khan; David Fasel; Teri A Manolio; Gail P Jarvik; Robb Rowley; Ann E Justice; Alanna K Rahm; Stephanie M Fullerton; Jordan W Smoller; Eric B Larson; Paul K Crane; Ozan Dikilitas; Georgia L Wiesner; Alexander G Bick; Mary Beth Terry; Chunhua Weng Journal: JAMA Netw Open Date: 2021-08-02